Hydrocortisone Milpharm (Hydrocortisone)

Hydrocortisone Milpharm is indicated for several clinical situations where glucocorticoid activity is required. It is commonly prescribed for:

• Replacement therapy in patients with adrenal insufficiency, such as Addison’s disease.
• Management of acute inflammatory episodes in autoimmune disorders.
• Supportive treatment of severe allergic reactions when systemic steroids are needed.
• Adjunct therapy in certain endocrine disorders to supplement endogenous cortisol levels.
• Short‑term use for stress dosing during surgery or severe illness.

• Hydrocortisone Milpharm acts as an agonist at intracellular glucocorticoid receptors. After binding, the drug‑receptor complex translocates to the nucleus where it interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokine production. This genomic effect reduces leukocyte infiltration, stabilizes lysosomal membranes, and decreases capillary permeability, providing both anti‑inflammatory and immunosuppressive actions.

Hydrocortisone Milpharm may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Increased appetite or weight gain.
• Mild gastrointestinal discomfort or nausea.
• Fluid retention leading to mild edema.
• Elevated blood glucose levels, especially in susceptible individuals.
• Mood changes such as irritability or mild anxiety.

Serious

• Severe hyperglycemia or new‑onset diabetes.
• Significant hypertension or cardiovascular events.
• Osteoporosis or increased fracture risk with prolonged use.
• Suppression of the hypothalamic‑pituitary‑adrenal axis.
• Opportunistic infections due to immunosuppression.

Before initiating Hydrocortisone Milpharm, certain precautions should be considered to minimize risk. Patients should be evaluated for:

• Existing infections, as glucocorticoids can exacerbate bacterial, viral, or fungal growth.
• Uncontrolled diabetes mellitus or hyperglycemia.
• Hypertension, cardiovascular disease, or history of thromboembolic events.
• Osteoporosis or a history of fractures.
• Pregnancy or breastfeeding status, given limited safety data.
• Potential for adrenal suppression; tapering may be required after long‑term therapy.

Hydrocortisone Milpharm can interact with several drug classes, influencing its efficacy or safety profile.

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone levels.
• Live vaccines, which may lead to inadequate immune response.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase risk of gastrointestinal bleeding.

Use with caution

• Antidiabetic agents, as glucocorticoids may raise blood glucose.
• Antihypertensive medications, because fluid retention can counteract blood pressure control.
• Anticoagulants, due to potential alterations in clotting factor balance.
• Other systemic steroids, which may increase risk of adrenal suppression and side effects.